Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alveltamig · 1 trial · 1 indication
Objective response (OR) is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) as assessed by Blinded Independent Central Review (BICR) per RECIST v1.1 prior to subsequent anti-cancer therapy.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| ABBV-706 Dose A + Alveltamig + Atezolizumab | EXPERIMENTAL | Participants will receive ABBV-706 dose A in combination with alveltamig and atezolizumab during the safety lead-in and dose expansion periods. |
| ABBV-706 Dose B + Alveltamig + Atezolizumab | EXPERIMENTAL | Participants will receive ABBV-706 dose B in combination with alveltamig and atezolizumab during the safety lead-in and dose expansion periods. |
| Name | Type | Description |
|---|---|---|
| Alveltamig | DRUG | Intravenous |
| Atezolizumab | DRUG | Intravenous |
| ABBV-706 | DRUG | Intravenous |
Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed extensive stage-small cell lung cancer (ES-SCLC) requiring treatment with first-line therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Must have measurable disease per RECIST v1.1 * Has an ...